




LATUDA = Lurasidone

Class




Atypical AntiPsychotic

- Serotonin-dopamine antagonist
- Second generation antipsychotic)
- Mood stabilizer


APPROVED FOR

- Schizophrenia 13+ 
- Bipolar Depression 10+ 
- Bipolar depression Adults  adjuvant


Formulation

- Tablet 20 mg, 
 - once daily with food
 - children and teens
 - once daily with food
 - single night dose
 - divided doses
 - schizophrenia
 - gradual increase
- 40 mg, 
 - once daily with food
 - Resistant schizophrenia
- 60 mg, 80 mg, 


PREGNANCY

- No Teratogenicity reported 
- Risk of abnormal child movements


Liver impairment

- max 40 mild 
- Max 20 Severe

KIDNEY

- Severe Impairment  80 mg max
- mild Impairment 80-120 & monitor

Pharmacokinetic

- half life 18-30 hours
- Cmax and bioavailability are reduced  take without food
- Metabolized CYP450 3A4

Side Effects

- Weight gain 
 - Not initial
 - 1 Kg /one year
- Sedation 
 - Early
 - short term
 - uncommon
- Dose dependent 
 - Akathisia
 - Dizziness
 - Nausea
 - May increase risk
 - DM  dislipidemia
 - Prolactinaemia
 - Tachy-cardia
- Contraindication 
 - patient is taking a strong CYP 3A4
 - Inducer Rifampin
 - Inhibitor ketoconazole